Resona Asset Management Co. Ltd. Sells 46,004 Shares of Bristol Myers Squibb Company $BMY

Resona Asset Management Co. Ltd. decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 6.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 691,127 shares of the biopharmaceutical company’s stock after selling 46,004 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Bristol Myers Squibb were worth $31,065,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Brighton Jones LLC grew its stake in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares during the last quarter. American National Bank & Trust grew its position in shares of Bristol Myers Squibb by 17.3% during the second quarter. American National Bank & Trust now owns 2,317 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 342 shares in the last quarter. ST Germain D J Co. Inc. increased its holdings in shares of Bristol Myers Squibb by 6.4% in the second quarter. ST Germain D J Co. Inc. now owns 21,558 shares of the biopharmaceutical company’s stock worth $998,000 after purchasing an additional 1,303 shares during the last quarter. Finally, Patton Fund Management Inc. purchased a new stake in shares of Bristol Myers Squibb in the second quarter worth about $213,000. Institutional investors own 76.41% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY struck a sizable collaboration and exclusive license deal with Janux Therapeutics (worth up to ~$800M), signaling near‑term external innovation that could bolster BMY’s oncology pipeline and near‑term partnering upside. Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
• Positive Sentiment: BMY and BioNTech advanced a Phase 3 lung‑cancer program for pumitamig, a potential new competitor to Keytruda — a successful readout would be material to oncology revenue upside. Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial
• Positive Sentiment: BMY reported progress in a China mesothelioma trial for Opdivo + Yervoy, which signals additional oncology label/market expansion opportunities in a large market. Bristol Myers Squibb Advances Opdivo/Yervoy in China Mesothelioma Trial, Signaling New Oncology Upside
• Positive Sentiment: BMY announced a collaboration with Microsoft to develop AI‑driven early detection tools for lung cancer — a strategic move that could accelerate diagnostics-linked R&D and potential data/technology synergies. Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
• Positive Sentiment: Analysts at UBS turned more constructive on biotech/pharma, including BMY exposure, which supports investor sentiment around sector recovery and dividend stability. Bristol-Myers (BMY): UBS turns bullish as biotech and pharma show signs of a recovery
• Neutral Sentiment: Coverage pieces are re‑evaluating BMY’s valuation and pipeline after the Microsoft pact and Camzyos trial news — useful context but not an immediate earnings swing. A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results
• Neutral Sentiment: Analyst action: Citi placed BMY at a Hold, tempering upside expectations from some investors even as clinical headlines roll in. Bristol-Myers Squibb (BMY) Receives a Hold from Citi
• Negative Sentiment: An analyst lowered Q1 EPS estimates for BMY, adding short‑term earnings pressure and a reason for cautious positioning ahead of upcoming quarterly/clinical readouts. Q1 EPS Estimate for Bristol Myers Squibb Lowered by Analyst
• Neutral Sentiment: Stock commentary noting “mixed returns and pipeline developments” flags that while R&D catalysts are meaningful, execution risk and valuation remain focal for investors. Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline Developments

Analysts Set New Price Targets

BMY has been the subject of several research analyst reports. Scotiabank restated a “sector perform” rating and set a $60.00 price target (up previously from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Morgan Stanley reissued an “underweight” rating and issued a $37.00 target price (up from $36.00) on shares of Bristol Myers Squibb in a report on Friday, December 12th. Truist Financial set a $65.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, December 3rd. Leerink Partners boosted their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $56.86.

Bristol Myers Squibb Trading Down 0.6%

Shares of BMY opened at $54.61 on Friday. The company’s fifty day simple moving average is $52.57 and its 200-day simple moving average is $48.40. The company has a market cap of $111.17 billion, a P/E ratio of 18.45, a P/E/G ratio of 0.17 and a beta of 0.29. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. During the same period in the prior year, the business posted $1.80 earnings per share. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is 85.14%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.